Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CFO Joseph Walter Vazzano purchased 5,608 shares of Abeona Therapeutics stock in a transaction on Thursday, April 25th. The stock was bought at an average price of $3.14 per share, with a total value of $17,609.12. Following the transaction, the chief financial officer now owns 233,868 shares of the company's stock, valued at $734,345.52. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Abeona Therapeutics Price Performance
Shares of Abeona Therapeutics stock opened at $3.26 on Friday. Abeona Therapeutics Inc has a 12 month low of $2.83 and a 12 month high of $9.01. The stock has a 50 day moving average of $7.31 and a 200 day moving average of $5.61.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.13). As a group, analysts forecast that Abeona Therapeutics Inc will post -2.05 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Did You Get Your Free Bitcoin Yet?
From Crypto Swap Profits | Ad
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously.
Right now is a very important time to pay attention to what we are doing and what is happening.
If you wait... it will be too late.
This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
>> Register right here
Several institutional investors have recently bought and sold shares of the company. Simplex Trading LLC increased its holdings in shares of Abeona Therapeutics by 1,889.9% in the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company's stock valued at $59,000 after acquiring an additional 13,418 shares during the period. Jump Financial LLC purchased a new position in shares of Abeona Therapeutics in the 4th quarter valued at $199,000. Worth Venture Partners LLC increased its holdings in shares of Abeona Therapeutics by 76.6% in the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company's stock valued at $1,184,000 after acquiring an additional 121,969 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Abeona Therapeutics in the 3rd quarter valued at $648,000. Finally, Barclays PLC increased its holdings in shares of Abeona Therapeutics by 100.0% in the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company's stock valued at $1,564,000 after acquiring an additional 185,638 shares during the period. 80.56% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of analysts have commented on ABEO shares. StockNews.com cut Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating and set a $36.00 target price on shares of Abeona Therapeutics in a research report on Tuesday.
Check Out Our Latest Research Report on Abeona Therapeutics
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
